Want to see TSHA full AI Analyst Report?
Top Page
Taysha Gene Therapies
(NASDAQ:TSHA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.00
▼(-33.55% Downside)
Action:Reiterated
Date:10/07/26
The score is held back primarily by weak financial performance (large ongoing losses and cash burn with limited/declining revenue) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a strong earnings-call outlook centered on clinical efficacy durability, manufacturing/regulatory progress toward a BLA pathway, and extended cash runway into H2 2028.
Positive Factors
Clinical efficacy and durability
The reported response rates materially exceeded the FDA-aligned threshold and improved with follow-up, supporting the potential for durable treatment benefit. Sustained functional gains across multiple developmental domains could strengthen the product’s clinical differentiation and future regulatory case.
Negative Factors
Persistent cash burn and losses
Material operating and free-cash-flow losses show that Taysha’s current activities consume substantial capital before any product revenue is established. Continued losses can reduce financial flexibility over time and increase reliance on cash reserves or future external funding to complete development.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and durability
The reported response rates materially exceeded the FDA-aligned threshold and improved with follow-up, supporting the potential for durable treatment benefit. Sustained functional gains across multiple developmental domains could strengthen the product’s clinical differentiation and future regulatory case.
Read all positive factors
Taysha Gene Therapies (TSHA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.34B
Dividend YieldN/A
Average Volume (3M)4.60M
Price to Earnings (P/E)―
Beta (1Y)2.76
Revenue Growth-32.27%
EPS Growth-21.09%
CountryUS
Employees99
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding325,833,560
10 Day Avg. Volume5,153,564
30 Day Avg. Volume4,603,785
Financial Highlights & Ratios
PEG Ratio2.91
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue385.54
Enterprise Value/Gross Profit459.21
Enterprise Value/Ebitda-14.20
Forecast
1Y Price Target
$14.00Price Target Upside132.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$2.18M
Taysha Gene Therapies Business Overview & Revenue Model
Company Description
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous ...
How the Company Makes Money
As a clinical-stage gene therapy company, Taysha has historically not generated material recurring revenue from product sales; accordingly, information about ongoing commercial revenue streams is not available. Based on typical disclosures for TSH...
Taysha Gene Therapies Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and operational progress: dosing completion in pivotal and supportive trials, robust Part A efficacy (well above the FDA-aligned 33% threshold), durable multi-domain functional gains, a favorable safety profile to date with a single manageable Grade 2 SAE, secured commercial manufacturing and an expanded Catalent partnership, and a strengthened balance sheet with $455.4M in cash providing runway into H2 2028. Headwinds include substantial increases in R&D and G&A expense driving a wider net loss, the occurrence of an AAV-associated neuropathy event that underscores ongoing safety monitoring needs, and residual uncertainties from small cohort sizes and a single-arm registrational approach (though DMA validation and natural history data mitigate some risk). Overall, the positives — particularly the efficacy durability and strengthened manufacturing and financial readiness — materially outweigh the disclosed risks and costs.Positive Updates
Completion of Dosing in Key Clinical Trials
Dosing completed in the over-enrolled REVEAL pivotal trial (17 patients) and in the ASPIRE trial (4 patients), with 33 total patients treated across REVEAL Phase I/II pivotal and ASPIRE as of the August 2026 cutoff.
Negative Updates
Increased Operating Expenses
R&D expense rose to $38.6 million for Q2 2026 from $20.1 million in Q2 2025 (increase of $18.5M, ~92% year-over-year) driven by BLA-enabling PPQ manufacturing and higher clinical costs; G&A rose to $12.1M from $8.6M (increase of $3.5M, ~41% YoY).
Read all updates
Q2-2026 Updates
Positive
Negative
Completion of Dosing in Key Clinical Trials
Dosing completed in the over-enrolled REVEAL pivotal trial (17 patients) and in the ASPIRE trial (4 patients), with 33 total patients treated across REVEAL Phase I/II pivotal and ASPIRE as of the August 2026 cutoff.
Read all positive updates
Company Guidance
Taysha guided that it expects to complete BLA‑enabling PPQ in Q4 2026 and to report topline results from the REVEAL pivotal 6‑month interim analysis and receive FDA feedback on the BLA pathway in H1 2027 (noting a potential acceleration of filing by at least two quarters if filing on 6‑month vs 12‑month data); as of June 30, 2026 the company had $455.4M cash and equivalents (including $230M gross proceeds from the June follow‑on) and expects that cash to fund operations into the second half of 2028; Q2 2026 R&D expense was $38.6M, G&A $12.1M and net loss $46.6M (‑$0.13/share). Clinical guidance/metrics noted that dosing is complete in the REVEAL pivotal (17 patients) and ASPIRE (4 patients) trials with 33 patients treated total as of the August 2026 cutoff and >3 years since first dosing; Part A (n=12) showed developmental milestone responder rates of 75% at 3 months, 83% at 6 months and 100% at 12 months versus the FDA‑aligned 33% threshold, with 31 developmental milestones achieved and 310 functional gains (avg. ~26 gains/patient) at ≥12 months; safety: no severe treatment‑related SAEs or dose‑limiting toxicities reported across 33 patients, with one moderate (Grade 2) AAV‑associated peripheral sensory neuropathy that was treated and rapidly improved.Taysha Gene Therapies Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 9.77M | 8.33M | 15.45M | 2.50M | 0.00 |
| Gross Profit | 4.61M | 9.77M | 8.33M | 15.45M | 15.00K | 0.00 |
| EBITDA | -148.88M | -107.79M | -87.95M | -105.20M | -161.04M | -172.60M |
| Net Income | -149.63M | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M |
Balance Sheet | ||||||
| Total Assets | 470.43M | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M |
| Cash, Cash Equivalents and Short-Term Investments | 455.41M | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M |
| Total Debt | 55.55M | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M |
| Total Liabilities | 83.17M | 96.38M | 88.84M | 97.79M | 125.33M | 118.57M |
| Stockholders Equity | 387.27M | 246.94M | 71.53M | 74.94M | 949.00K | 95.38M |
Cash Flow | ||||||
| Free Cash Flow | -135.57M | -93.83M | -81.60M | -80.39M | -113.26M | -138.60M |
| Operating Cash Flow | -132.19M | -93.09M | -81.22M | -73.02M | -88.39M | -117.04M |
| Investing Cash Flow | -3.32M | -604.00K | -363.00K | -7.35M | -24.93M | -21.55M |
| Financing Cash Flow | 275.72M | 274.59M | 76.68M | 136.39M | 52.10M | 39.08M |
Taysha Gene Therapies Technical Analysis
Negative
6.02
Price Trends
5.06
Negative
5.56
Negative
5.35
Negative
Market Momentum
-0.34
Negative
38.88
Neutral
56.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Negative. The current price of 6.02 is above the 20-day moving average (MA) of 4.29, above the 50-day MA of 5.06, and above the 200-day MA of 5.35, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 38.88 is Neutral, neither overbought nor oversold. The STOCH value of 56.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSHA.
Taysha Gene Therapies Risk Analysis
Taysha Gene Therapies disclosed 83 risk factors in its most recent earnings report. Taysha Gene Therapies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Taysha Gene Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $957.55M | 12.97 | 284.38% | ― | 948.35% | ― | |
53 Neutral | $1.58B | -5.62 | -111.96% | ― | 30.24% | -3.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.34B | -9.75 | -56.19% | ― | -32.27% | -21.09% | |
49 Neutral | $1.96B | -12.89 | -9.96% | ― | -20.44% | -349.84% | |
49 Neutral | $1.57B | -2.73 | 392.35% | ― | 17.50% | -5.66% | |
44 Neutral | $488.50M | -1.89 | -220.07% | ― | 12.00% | -9.21% |
* Healthcare Sector Average
TSHA
Taysha Gene Therapies
4.01
-0.94
-18.93%
SRPT
Sarepta Therapeutics
18.18
-3.71
-16.95%
RARE
Ultragenyx Pharmaceutical
15.95
-17.68
-52.57%
QURE
uniQure
23.11
-36.22
-61.05%
RGNX
RegenXBio
7.17
-5.41
-43.00%
MGTX
Meiragtx Holdings
9.77
1.02
11.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.